Safety of antithrombotic therapy in subjects with hereditary hemorrhagic telangiectasia: prospective data from a multidisciplinary working group

Subjects with the rare autosomal dominant disease Hereditary Hemorrhagic Telangiectasia (HHT) may develop medical conditions that require antithrombotic therapy (AT). However, safety of AT is uncertain in these patients and the only data currently available derive from retrospective analyses of regi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaetani, Eleonora, Agostini, Fabiana, Porfidia, Angelo, Giarretta, Igor, Feliciani, Daniela, Di Martino, Luigi, Tortora, Annalisa, Gasbarrini, Antonio, Pola, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933630/
https://www.ncbi.nlm.nih.gov/pubmed/31878955
http://dx.doi.org/10.1186/s13023-019-1278-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933630/
https://www.ncbi.nlm.nih.gov/pubmed/31878955
http://dx.doi.org/10.1186/s13023-019-1278-z

Ejemplares similares